*The following content is generated by AI and is for reference only.
Gimeracil, chemically known as 5-fluoro-2(1H)-pyridone or more accurately as a specific derivative in the context of anticancer therapy, is frequently identified by its CAS number 97643-82-0. It serves as a critical component in the combination chemotherapy regimen known as S-1, often paired with tegafur and gliclazide (or capecitabine in other formulations), though it is most notably recognized for its synergistic role when combined with uracil in the drug TAS-102 or specifically in the fixed-dose combination with tegafur and oxaliplatin. Its primary molecular formula is C5H4FNO2, reflecting its structure as a fluorinated pyridinone derivative designed to inhibit dihydropyrimidine dehydrogenase (DPD). This enzyme is responsible for the catabolism of 5-fluorouracil (5-FU); by inhibiting DPD, Gimeracil prevents the rapid breakdown of 5-FU, thereby significantly prolonging its half-life and enhancing its cytotoxic effects on tumor cells without increasing systemic toxicity.
The therapeutic application of Gimeracil is predominantly focused on the treatment of gastrointestinal malignancies, including gastric cancer, colorectal cancer, and esophageal cancer. By maintaining higher intracellular concentrations of active 5-FU metabolites, it allows for more effective DNA synthesis inhibition and cell cycle arrest in rapidly dividing cancer cells. Clinical studies have demonstrated that regimens containing Gimeracil offer improved survival rates and reduced side effects compared to traditional 5-FU monotherapy. The compound is typically administered orally in tablet form as part of a standardized protocol. Its mechanism relies on the precise modulation of fluoropyrimidine pharmacokinetics, making it a cornerstone in modern oncology for optimizing chemotherapy efficacy. While generally well-tolerated, patients may experience mild hematological or gastrointestinal adverse events, necessitating careful monitoring during treatment cycles. As research continues, Gimeracil remains a vital agent in expanding the arsenal against refractory solid tumors, highlighting the importance of metabolic inhibitors in precision medicine strategies.